$BPTH News

Bio-Path Holdings Q1 EPS $(0.03) Up From $(0.40) YoY

Bio-Path Holdings Q2 EPS $(0.55) Misses $(0.40) Estimate

Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Bio-Path Holdings Provides Clinical and Operational Update

Bio-Path Holdings Highlights Pipeline Progress And Market Strategy For DNAbilize Platform

Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

Bio-Path: Q1 Earnings Snapshot

Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

Bio-Path Holdings Says It Has Secured Third Pre-Clinical Milestone Confirming Potential Of BP1001-A As Treatment For Obesity In Type 2 Diabetes Patients

Bio-Path Holdings Reports Full Year 2024 Financial Results

Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Bio-Path Holdings Expands Global Patent Portfolio

Bio-Path Holdings Receives Patent No. 17/339,366 Titled, "P-ethoxy nucleic acids for STAT3 inhibition." From United States Patent And Trademark Office

Bio-Path Holdings Provides Key Clinical Updates

Bio-Path Announces Tumor Reduction And Stable Disease In Phase 1/1b BP1001-A Trial At Higher Dose; Reports Patient Progress In Phase 2 AML Study With Prexigebersen

Bio-Path Holdings Provides Update from Phase 1/1b Clinical Trial of BP1002 for Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Bio-Path Holdings shares are trading higher after the company provided an update from its Phase 1/1b clinical trial of BP1002.

Bio-Path Holdings Provides Update From Phase 1/1b Clinical Trial Of BP1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia; Meaningful Patient Response Seen; Trial Advances To 90 mg Dose Cohort